This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CHIR-12.12, Lucatumumab
Description: CHIR-12.12 is a fully human, antagonist antibody that targets the CD40 antigen. As shown in vitro in cell lines, in vivo in animal models and ex vivo in patient cells, CHIR-12.12 binds to tumor cells that express CD40 and antagonizes CD40 ligand-mediated growth and survival of malignant B cells. CHIR-12.12 also induces antibody-dependent cellular cytotoxicity (ADCC), killing CD40 expressing tumor cells by immune effector cells. This dual mechanism of action makes CHIR-12.12 a promising drug candidate for thetreatment of B-cell malignancies.
Deal Structure: Chiron Corporation and XOMA Ltd. announced a worldwide, exclusive, multi-product, collaborative agreement in March 2004 for the development and commercialization of antibody products for the treatment of cancer. Under the terms of the agreement, the companies will jointlyresearch, develop, and commercialize multiple antibody product candidates.
Under the agreement, the companies will share development and commercialization expenses, including preclinical and clinical development,manufacturing, and worldwide marketing costs, as well as revenues, generally on a 70-30 basis, with Chiron's share being 70% and XOMA's share being 30%. XOMA will receive an initial payment of $10 million and a loan facility of upto $50 million to fund its share of development expenses. The collaboration will initially focus on preclinical, process development and scale up work, with a potential Investigative New Drug (IND) filing anticipated early on in the collaboration.
Chiron Corporation was a...See full deal structure in Biomedtracker
Partners: XOMA Corporation
Additional information available to subscribers only: